Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EIF3G

Gene summary for EIF3G

Gene summary.

Gene information	Species	Human
	Gene symbol	EIF3G
	Gene ID	8666
	Gene name	eukaryotic translation initiation factor 3 subunit G
	Gene Alias	EIF3-P42
	Cytomap	19p13.2
	Gene Type	protein-coding
	GO ID	GO:0001732
	UniProtAcc	O75821

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
8666	EIF3G	CA_HPV_1	Human	Cervix	CC	1.24e-12	-3.49e-01	0.0264
8666	EIF3G	CA_HPV_3	Human	Cervix	CC	1.15e-02	1.46e-01	0.0414
8666	EIF3G	N_HPV_1	Human	Cervix	N_HPV	1.16e-02	-1.23e-01	0.0079
8666	EIF3G	CCI_1	Human	Cervix	CC	1.71e-12	-7.54e-01	0.528
8666	EIF3G	CCI_2	Human	Cervix	CC	2.43e-07	-6.47e-01	0.5249
8666	EIF3G	CCI_3	Human	Cervix	CC	1.44e-13	-7.12e-01	0.516
8666	EIF3G	CCII_1	Human	Cervix	CC	2.62e-21	-7.40e-01	0.3249
8666	EIF3G	sample3	Human	Cervix	CC	3.48e-07	-2.45e-01	0.1387
8666	EIF3G	H2	Human	Cervix	HSIL_HPV	1.13e-02	-2.72e-01	0.0632
8666	EIF3G	L1	Human	Cervix	CC	1.68e-08	-3.38e-01	0.0802
8666	EIF3G	T1	Human	Cervix	CC	2.93e-07	-4.08e-01	0.0918
8666	EIF3G	T3	Human	Cervix	CC	1.23e-05	-2.63e-01	0.1389
8666	EIF3G	HTA11_3410_2000001011	Human	Colorectum	AD	1.51e-09	3.38e-01	0.0155
8666	EIF3G	HTA11_2487_2000001011	Human	Colorectum	SER	3.08e-09	4.14e-01	-0.1808
8666	EIF3G	HTA11_2951_2000001011	Human	Colorectum	AD	3.55e-03	5.06e-01	0.0216
8666	EIF3G	HTA11_1938_2000001011	Human	Colorectum	AD	1.66e-12	5.86e-01	-0.0811
8666	EIF3G	HTA11_78_2000001011	Human	Colorectum	AD	5.56e-11	4.12e-01	-0.1088
8666	EIF3G	HTA11_347_2000001011	Human	Colorectum	AD	2.49e-25	6.54e-01	-0.1954
8666	EIF3G	HTA11_411_2000001011	Human	Colorectum	SER	2.89e-03	6.91e-01	-0.2602
8666	EIF3G	HTA11_2112_2000001011	Human	Colorectum	SER	2.46e-02	6.51e-01	-0.2196

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000218110	Cervix	CC	cytoplasmic translation	96/2311	148/18723	4.87e-51	2.91e-47	96
GO:001603210	Cervix	CC	viral process	109/2311	415/18723	5.40e-15	6.46e-12	109
GO:002261310	Cervix	CC	ribonucleoprotein complex biogenesis	88/2311	463/18723	2.11e-05	3.82e-04	88
GO:002261810	Cervix	CC	ribonucleoprotein complex assembly	49/2311	220/18723	2.52e-05	4.29e-04	49
GO:007182610	Cervix	CC	ribonucleoprotein complex subunit organization	49/2311	227/18723	5.91e-05	8.54e-04	49
GO:00064139	Cervix	CC	translational initiation	25/2311	118/18723	4.54e-03	2.75e-02	25
GO:00190807	Cervix	CC	viral gene expression	21/2311	94/18723	4.68e-03	2.82e-02	21
GO:00021839	Cervix	CC	cytoplasmic translational initiation	10/2311	34/18723	6.40e-03	3.58e-02	10
GO:00017329	Cervix	CC	formation of cytoplasmic translation initiation complex	6/2311	16/18723	9.35e-03	4.66e-02	6
GO:00190817	Cervix	CC	viral translation	6/2311	16/18723	9.35e-03	4.66e-02	6
GO:000218115	Cervix	HSIL_HPV	cytoplasmic translation	86/737	148/18723	3.97e-82	1.91e-78	86
GO:002261315	Cervix	HSIL_HPV	ribonucleoprotein complex biogenesis	52/737	463/18723	9.85e-12	6.81e-09	52
GO:002261815	Cervix	HSIL_HPV	ribonucleoprotein complex assembly	29/737	220/18723	1.19e-08	1.30e-06	29
GO:007182615	Cervix	HSIL_HPV	ribonucleoprotein complex subunit organization	29/737	227/18723	2.42e-08	2.18e-06	29
GO:001603215	Cervix	HSIL_HPV	viral process	41/737	415/18723	6.43e-08	4.49e-06	41
GO:000641314	Cervix	HSIL_HPV	translational initiation	16/737	118/18723	1.56e-05	4.80e-04	16
GO:000218314	Cervix	HSIL_HPV	cytoplasmic translational initiation	8/737	34/18723	4.06e-05	1.08e-03	8
GO:000173214	Cervix	HSIL_HPV	formation of cytoplasmic translation initiation complex	5/737	16/18723	2.83e-04	4.69e-03	5
GO:000218125	Cervix	N_HPV	cytoplasmic translation	42/534	148/18723	2.61e-30	1.19e-26	42
GO:001603225	Cervix	N_HPV	viral process	33/534	415/18723	1.23e-07	1.15e-05	33

Page: 1 2 3 4 5 6 7 8 9 10 11

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EIF3G

SNV

Missense_Mutation

c.133N>T

p.Pro45Ser

p.P45S

O75821

protein_coding

tolerated(0.35)

possibly_damaging(0.901)

TCGA-C8-A135-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

EIF3G

SNV

Missense_Mutation

c.248N>A

p.Arg83His

p.R83H

O75821

protein_coding

deleterious(0.05)

probably_damaging(0.98)

TCGA-D8-A1XK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine+cyclophosphamide

EIF3G

SNV

Missense_Mutation

rs771861822

c.23N>T

p.Ser8Leu

p.S8L

O75821

protein_coding

tolerated(0.39)

benign(0.007)

TCGA-EA-A3HR-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

EIF3G

SNV

Missense_Mutation

c.49N>A

p.Glu17Lys

p.E17K

O75821

protein_coding

deleterious(0.02)

benign(0.14)

TCGA-EK-A2PM-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

EIF3G

SNV

Missense_Mutation

c.8N>T

p.Thr3Ile

p.T3I

O75821

protein_coding

deleterious(0.04)

benign(0.027)

TCGA-AA-3713-01

Colorectum

colon adenocarcinoma

Male

>=65

III/IV

Chemotherapy

5-fluorouracil

EIF3G

SNV

Missense_Mutation

rs868284931

c.715N>A

p.Ala239Thr

p.A239T

O75821

protein_coding

tolerated(0.25)

probably_damaging(0.945)

TCGA-CK-4951-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

EIF3G

SNV

Missense_Mutation

novel

c.664G>A

p.Ala222Thr

p.A222T

O75821

protein_coding

deleterious(0.01)

benign(0.154)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

EIF3G

SNV

Missense_Mutation

novel

c.404A>T

p.Glu135Val

p.E135V

O75821

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-AJ-A3EK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

EIF3G

SNV

Missense_Mutation

c.621G>T

p.Gln207His

p.Q207H

O75821

protein_coding

tolerated(0.12)

benign(0.188)

TCGA-AP-A0LM-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

EIF3G

SNV

Missense_Mutation

rs747937250

c.127C>T

p.Pro43Ser

p.P43S

O75821

protein_coding

tolerated_low_confidence(0.69)

benign(0)

TCGA-AP-A0LM-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1